RT308

RT308 is a preclinical-stage drug candidate being developed by Revio Therapeutics as part of its reformulation pipeline. The program focuses on enhancing a proven therapeutic agent for applications in haematology through the use of an optimized delivery system, specifically a multi-dose pen. This delivery method suggests a subcutaneous route of administration intended to improve patient convenience and adherence. As part of Revio's strategy to optimize proven drugs, RT308 aims to provide improved therapeutic profiles or delivery characteristics compared to existing versions of the active ingredient. As of early 2024, the specific active ingredient and molecular target remain undisclosed by the company.